Hikma Pharmaceuticals PLC - Asset Resilience Ratio
Hikma Pharmaceuticals PLC (HIK) has an Asset Resilience Ratio of 0.49% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Hikma Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hikma Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX25.00 Million | 0.49% |
| Total Liquid Assets | GBX25.00 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Hikma Pharmaceuticals PLC maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hikma Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Hikma Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.72% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
Annual Asset Resilience Ratio for Hikma Pharmaceuticals PLC (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Hikma Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | GBX25.00 Million | GBX5.13 Billion | -0.03pp |
| 2023-12-31 | 0.51% | GBX24.00 Million | GBX4.68 Billion | +0.02pp |
| 2022-12-31 | 0.49% | GBX22.00 Million | GBX4.47 Billion | -0.06pp |
| 2021-12-31 | 0.55% | GBX24.00 Million | GBX4.37 Billion | -0.03pp |
| 2020-12-31 | 0.58% | GBX24.00 Million | GBX4.13 Billion | 0.00pp |
| 2019-12-31 | 0.59% | GBX23.00 Million | GBX3.93 Billion | -0.02pp |
| 2018-12-31 | 0.60% | GBX21.00 Million | GBX3.50 Billion | -0.05pp |
| 2017-12-31 | 0.65% | GBX22.00 Million | GBX3.39 Billion | +0.19pp |
| 2016-12-31 | 0.46% | GBX20.00 Million | GBX4.36 Billion | -0.31pp |
| 2015-12-31 | 0.77% | GBX20.00 Million | GBX2.60 Billion | +0.41pp |
| 2014-12-31 | 0.36% | GBX8.00 Million | GBX2.25 Billion | -0.01pp |
| 2013-12-31 | 0.36% | GBX7.00 Million | GBX1.93 Billion | -0.28pp |
| 2012-12-31 | 0.64% | GBX11.04 Million | GBX1.73 Billion | +0.47pp |
| 2011-12-31 | 0.16% | GBX2.60 Million | GBX1.58 Billion | -0.16pp |
| 2010-12-31 | 0.32% | GBX3.57 Million | GBX1.12 Billion | +0.09pp |
| 2009-12-31 | 0.23% | GBX2.33 Million | GBX1.02 Billion | +0.14pp |
| 2008-12-31 | 0.08% | GBX819.00K | GBX966.46 Million | -0.54pp |
| 2007-12-31 | 0.63% | GBX5.63 Million | GBX894.04 Million | -0.46pp |
| 2006-12-31 | 1.09% | GBX5.34 Million | GBX488.36 Million | -0.19pp |
| 2005-12-31 | 1.29% | GBX5.12 Million | GBX397.96 Million | -1.83pp |
| 2004-12-31 | 3.12% | GBX7.69 Million | GBX246.48 Million | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more